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REVIEW
Abstract: Persistent infection by ‘high risk’ genotypes of human papilloma virus (HPV) is
necessary but not sufficient for the development of over 98% of cervical cancers. Thus the
development of vaccines that prevent HPV transmission represent an important opportunity
to prevent cervical cancer. There are several prophylactic HPV vaccine formulations based
upon L1 virus-like particles (VLPs) currently in phase III trials and recently released data are
extremely promising. However, many practical issues surrounding implementation of these
vaccines need to be addressed including, who and when to vaccinate, duration of protection,
and integration with current screening programs. The vaccines currently being evaluated target
the two most prevalent high risk HPV types which are responsible for approximately 70% of
cervical cancers. To increase the breadth of protection, it is likely that L1 VLPs of other viral
subtypes must be included, although vaccines targeting the conserved regions of the L2 minor
capsid protein warrant further exploration in this regard. In addition the vaccines nearing
licensing will not combat established HPV-related disease and a therapeutic vaccine, of which
there are several candidates in early stages of development, would be desirable. This review
discusses the background to and progress in vaccine development and the issues surrounding
the introduction of HPV vaccines.
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Pathology
Since Harold zur Hausen (1981) first linked papillomavirus to cervical cancer, two
decades of studies have confirmed that persistent infection with certain human
papilloma virus (HPV) genotypes termed ‘high risk’ is a necessary first carcinogenic
step, or ‘hit’ in the pathogenesis of cervical cancer (Walboomers et al 1999).
The complete papillomaviral life cycle is restricted to the human keratinocyte
and strictly dependant upon their differentiation. The virus is transmitted through
skin to skin contact and is thought to reach the basal keratinocyte via tiny breaches in
the epithelium to initiate infection; viral DNA is then replicated episomally using the
viral E1 and E2 proteins and the cellular DNA replication machinery. Expression of
the viral oncoproteins E5, E6, and E7 delays cell cycle arrest and the differentiation
which occurs as the epithelial cell parts from the basal layer and matures. In the
superficial layers of the epithelium, the structural proteins L1 and L2 are expressed
and assemble around the viral episomes to form mature virions in the cell nucleus.
Virions are released from the epithelium within the superficial epithelial cells.
Oncogenic progression is infrequent, but is associated with integration of high
risk type HPV viral DNA into the host genome. HPV DNA integration leads to
prolongation of the cell lifespan and results in dysplasia. Integration promotes
progression, but dysplasias (at least low grade) are also induced by the normal life
cycle of the virus, when the genome is episomal. Integration generally disrupts the
E2 gene which derepresses the expression of E6 and E7. High risk HPV E6 and E7
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products modulate a number of other pathways critical
to the transformed state, most notably the human
suppressor gene products p53 and pRb respectively. This
leads to failure of cell cycle check point control and
genomic instability allowing accumulation of damaged
genes and facilitating the evolution of invasive cancer
(Frazer 2004; Doorbar 2005). Since the E6 and E7
proteins are driving the neoplastic process, and their loss
triggers apoptosis, they are obvious therapeutic vaccine
targets.
Epidemiology
It has been estimated that 5.5% of the worldwide
incidence of cancer in 2002 was attributable to HPV
infection. The majority of HPV-related cancers derive
from the uterine cervix, although HPV is probably also a
causal factor in some head and neck cancers and a number
of other anogenital cancers (Parkin 2005).
Cervical cancer is the second most common malignant
neoplasm affecting women worldwide and accounts for
nearly 10% of all cancers in women. It is estimated that
493 000 new cases were diagnosed in 2002, 83% of these
in developing countries (Parkin et al 2005). In terms of
mortality, an estimated 273 000 deaths from cervical
cancer occur worldwide each year again with over three
quarters of them in developing countries (Ferlay et al
2001).
Although less prevalent in developed countries with
effective screening programs, cervical cancer still
accounts for 3.6% of all new cancers (Parkin et al 2005).
Indeed in 2003 there were 2312 new registrations of
invasive cervical cancer in England (ONS 2005a)
Although most of the more than 100 HPV types
produce benign lesions, a small subset of genotypes are
strongly associated with the development of cervical
cancer. This subset has been classified as ‘high risk’ and
includes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, and
58. More recently genotypes 59, 68, 73, and 82 have been
newly identified as high risk, while types 26, 53, and 66
have been designated as probable high risk types (IARC
2005). It has been estimated that a vaccine completely
effective against only the two most common high risk
HPV types, namely types 16 and 18 could prevent 71%
of cervical cancers worldwide. A vaccine containing the
seven most common high risk HPV types might prevent
around 87% of cervical cancers worldwide with little
regional variation (Munoz et al 2004).
Current prevention strategies and
treatments
The dysplastic process develops over 1–2 decades, providing
a window for structured screening programs to detect and
ablate pre-invasive disease.
Since the introduction of call and recall screening in the
UK in 1988, cervical cancer rates have halved from 16.5
per 100 000 in 1988 to 8.6 per 100 000 in 2001 (ONS 2005b).
It has been estimated that cervical screening prevents around
5000 deaths per year in the UK. Indeed given the rising
rates of HPV infection attributable to changes in patterns of
sexual behavior this may be an underestimate (Peto et al
2004).
Following reports from pilot studies, in 2003 the National
Institute for Health and Clinical Excellence (NICE)
recommended that liquid based cytology become the
primary screening method in the UK. Newer technologies
including HPV DNA testing by hybrid capture are currently
under investigation as a primary screening test in a number
of trials including the ARTISTIC (A Randomised Trial of
HPV Testing in Primary Cervical Screening) trial in
Manchester (Kitchener et al 2005).
HPV testing appears to be more sensitive but less specific
for detecting high grade cervical intraepithelial neoplasia
(CIN) than cytology (Cuzick et al 2003). Its lack of
specificity lies in the fact that it will detect many transient
infections. HPV testing as a primary screening test with
cytological triage of those found to be HPV positive has
been proposed as a possible screening model. A repeat
testing interval of 12 months for those women found to be
HPV positive who have normal or borderline cytology has
been found to be as effective as immediate colposcopy
(Cuzick et al 2003). This has the potential to improve the
detection of high grade CIN without increasing the number
of women referred for colposcopy. However the social
acceptability of a nationwide screen for a sexually
transmitted infection and the psychological impact of a
positive test are factors which may impact on uptake rates.
Some of these issues are being addressed by the ARTISTIC
study. Currently the main obstacle to HPV testing is its high
cost which would need to be offset by savings resulting
from less pap smears being performed and/or longer
screening intervals.
Screening is currently aimed at detecting CIN and
treating high grade disease. This is because over 70% of
mild dysplasia including CIN I resolves spontaneously,
however 25% of CIN II progresses to severe dysplasia withinTherapeutics and Clinical Risk Management 2006:2(3) 261
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5 years and about 1/3 of CIN III progresses to cancer. Thus,
CIN 1 does not necessarily require treatment when detected.
However cytological and colposcopic follow up should be
performed until spontaneous regression has occurred or
treatment is required (NHSCSP 2004). In the future it may
be possible to limit follow up to only those women known
to have high risk HPV types.
In terms of current treatments, a Cochrane review of 28
trials suggested that there was no superior surgical technique
for treating CIN when considering knife cone, laser cone,
large loop excision of the transformation zone (LLETZ),
laser ablation, and cryotherapy. However LLETZ appeared
to provide the most reliable specimens for histology with
the least morbidity (Martin Hirsch et al 1999). Excisional
techniques are highly effective and one of the most widely
used techniques, the LLETZ has a success rate of 91%–
94% (Prendiville et al 1989). However this treatment does
not necessarily eliminate HPV from the upper genital tract
and there is a risk of recurrence. One can monitor residual
disease in follow up using cytology, histology of the margins
of excision, or even by high risk HPV detection. Any
treatment that can address the underlying HPV infection is
clearly preferable since physical removal has already failed.
Prevention of infection, by prophylactic vaccination, would
potentially eliminate the development of cervical cancer
whilst a successful therapeutic immunization would be
valuable in treating premalignant and malignant disease.
Report of studies of vaccine
developments
Vaccination is historically the most effective and inexpensive
approach to combat infectious disease. Thus there is a large
body of literature relating to vaccination against HPV and
cervical cancer (Frazer 2004; Kadish and Einstein 2005;
Mahdavi and Monk 2005; Stern 2005), but herein we will
highlight some of the most clinically relevant studies on
the topic.
Prophylactic vaccines
The discovery that the major viral capsid protein L1 self
assembles to form virus-like particles (VLPs) antigenically
similar to the native virus has driven preventative HPV
vaccine development (Zhou et al 1991; Ghim et al 1992;
Kirnbauer et al 1992; Rose et al 1994). These VLPs lack
the oncogenic viral DNA but elicit high titers of neutralizing
antibody that protect against experimental viral infection.
This was confirmed in several different animal models
(Breitburd et al 1995; Suzich et al 1995; Kirnbauer et al
1996).
Two vaccines currently under development, Gardasil
®
(Merck, Whitehouse Station, NJ, USA) and CervarixTM
(GlaxoSmithKline [GSK], Rixensart, Belgium), use this
technology. They both use HPV 16 and 18 L1 VLPs as the
basis of their cervical cancer preventive vaccines, but in
addition Merck has added HPV 6 and 11 to prevent benign
condylomata accuminata (90% of which are HPV 6 or 11
positive). The vaccines are highly immunogenic and appear
safe, with recipients displaying no significant adverse
effects. The efficacy of both vaccines in large phase II studies
has been impressive. Merck’s original formulation which
contained HPV 16 VLPs only was shown to have 100%
protection against persistent HPV infection. In their
landmark study of 1500 women published in 2002 all of
the 41 women who acquired persistent infections, defined
as two detections within 4 months, had received placebo.
The 9 cases of HPV 16-related CIN also occurred in placebo
recipients (Koutsky et al 2002). Notably, 22 cases of CIN
related to types other than HPV16 was reported in both the
placebo and vaccine arms, suggesting a considerable degree
of type specificity in protection. The 4 year follow up data
for this study has now been published. Among 755 vaccine
recipients there were no cases of HPV 16-related CIN 2 or
3 in the per protocol analysis in comparison with 12 cases
in the placebo recipients (Mao et al 2006). GSK reported
remarkably similar efficacy for their HPV16/18 vaccine in
2004, reporting 100% protection against persistent infection
in 700 vaccinated women. CIN was identified in 6 placebo
recipients and in one vaccinated woman who was infected
with a non-16/18 HPV type (Harper et al 2004). Evidence
of partial cross-protection against very related HPV types
(in prevention of abnormal cytology) was reported at the
International Papillomavirus Meeting (Dubin et al 2005)
and is consistent with findings of low titer cross-neutralizing
antibodies in vitro (Roden et al 1996).
Subsequent to these reports Merck have published results
of 500 women vaccinated with the quadrivalent vaccine
containing HPV16, 18, 6, and 11 VLPs, reporting an 89%
efficacy against persistent infection (Villa et al 2005). Only
one of the four cases in the vaccine group was a confirmed
persistent infection; other three were single time detections
at the last visit. Current studies by both companies aim to
show protection against development of intermediate and
high grade CIN which is more closely linked with
development of cervical cancer.Therapeutics and Clinical Risk Management 2006:2(3) 262
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Data from Merck’s ‘Future II’ study was presented at
the Infectious Diseases Society of America in October 2005
(Skjeldestad 2005). This phase III study of Gardasil
involving more than 12 000 women aged 16 to 26 showed
no cases of CIN in the per protocol vaccine arm and 21
cases of CIN in the placebo arm, suggesting 100% efficacy
against HPV types 16 and 18 associated CIN.
All the available data points to the vaccines being
extremely effective in preventing infection and CIN over a
relatively short period of time, but these studies rely on
prevention of CIN as a surrogate for cancer. Only after large
populations have been vaccinated, with many years of follow
up, could estimates of direct impact on cancer prevention
be made. Licensure of prophylactic vaccines is likely in late
2006 and key questions regarding the practical
implementation of these vaccines remain unresolved (Table
1).
An important issue that needs to be addressed before
vaccination programs can be successfully implemented is
public education. There is a lack of awareness of the link
between HPV and cervical cancer; for example, in a study
of 1032 women attending a well women clinic in the UK,
only 30% had heard of HPV and even among those who
had their knowledge was generally poor (Waller et al 2003).
Another difficult issue is the question of the age at which
to vaccinate. In order to be most effective the vaccine should
be given before first sexual intercourse. This would entail
gaining parental approval for vaccination of their children
which requires careful discussion and well coordinated
public education campaigns.
The duration of vaccine-induced immunity is as yet
unknown and vaccinating at 10–12 years old may be too
early to offer protection from the virus during the time when
most women are exposed. Only relatively short term follow
up data is available from the current studies. Data at 36
months post vaccination with Gardasil showed 94%
seropositivity for HPV 6, 11, and 16, and 76% of women
had antibody responses against HPV 18 (Villa et al 2005).
Longer follow up data and bridging studies are required to
clarify whether booster vaccinations will be required.
However, it is possible that T cell responses, including those
against early proteins, and not just neutralizing antibody,
are required for long term protection against HPV infection.
In addition to the oncogenic HPV types 16 and 18, Merck
have added HPV types 6 and 11 VLPs to their formulation.
The addition of these non-oncogenic types might provide
an incentive for men to receive the vaccine. However,
evidence that this vaccine is effective in men per se, or
effective in preventing benign genital warts and other HPV-
related disease in men is not yet available. Merck currently
have an ongoing trial to address the specific issue of the
efficacy of their quadrivalent vaccine in men. Even if
efficacy in men is proven, acceptability of male vaccination
may still prove a contentious area given the low rate of HPV-
associated malignancy in men. Will the essentially altruistic
motivation of preventing disease in their future partners be
sufficient to encourage parents to allow vaccination of their
boys?
A potential limitation of the current vaccines under
development is their HPV type specificity. Approximately
70% of cancers i.e. those caused by HPV types 16 and 18
may be prevented by the current vaccines. Adding protection
against HPV types 45 and 31 could prevent a further 10%
(Bosch et al 1995) assuming no cross protection.
Since prophylactic vaccines do not protect against all
HPV subtypes nor do they address the current burden of
pre-invasive and invasive disease, a role for continued
cervical screening programs integrated with vaccination in
a two pronged approach remains. One mathematical model
looking at clinical benefits and cost-effectiveness in the US
assumed conservatively that vaccination would not impact
on current screening practice; using this assumption the
model predicted that a HPV 16/18 vaccine ranging in
efficacy from 70%–100% would reduce the lifetime risk of
cancer by 46%–66%. The absolute lifetime risk would be
reduced from 0.86% to 0.3% (if 100% effective) and to
0.47% (if 70% effective) compared with current screening.
This model also examined the incremental cost-effectiveness
ratio (ICER) of introducing a HPV 16/18 vaccine using
various scenarios; this is the additional cost of a strategy
(in this case vaccination) divided by its additional clinical
Table 1 Contentious issues surrounding prophylactic vaccines
Prophylactic vaccines
Implementation issues
Age at wish to vaccinate
Vaccination of men
Duration of infection/need for booster doses
Coordination with screening programmes
Public education
Technology issues
Expense of manufacturing
Expense of distribution – cold chain
Type specificity
Combined therapeutic effectTherapeutics and Clinical Risk Management 2006:2(3) 263
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benefit compared with the next most expensive strategy.
Again using the assumption that vaccination would not alter
current screening practice they predicted that the ICER of a
HPV 16/18 vaccine would vary from $20 600 (100% vaccine
efficacy) −$33 700 (70% vaccine efficacy) per quality
adjusted life year depending on vaccine efficacy. Various
strategies combining primary prevention with vaccination
and secondary prevention with cytological screening were
also examined. The most effective strategy with an
incremental cost-effectiveness ratio of less than $60 000 per
quality adjusted life year is combining vaccination at age
12 years with triennial conventional cytological screening
beginning at age 25 years This would reduce the lifetime
risk of cancer by 94% compared with no intervention
(Goldie et al 2004).
The main financial benefit of HPV vaccines in
developed countries would be the cost savings made from
a reduction in the number of screen detected abnormal
cervical smears requiring further investigation each year.
In developing countries the main impact would be in a
reduction of the actual number of cervical cancer cases
and hence the overall financial burden of treating this
disease. However these benefits must be offset against
the expense of manufacturing and of distributing the
current HPV VLP vaccines.
A theoretical possibility is that once vaccines have
eliminated the commonest types HPV 16 and 18, the rarer
subtypes could expand in frequency to refill this ecological
niche. Although unlikely it will be necessary for health
providers to monitor for this possibility with post vaccination
surveillance. The natural history study being carried out by
the US National Cancer Institute in Costa Rica using the
bivalent 16/18 vaccine may go some way to answering this
and other questions.
An ideal vaccine to circumvent this problem would
protect against not only those HPV types contained in the
vaccine, but also induce antibodies that would protect
against other HPV types ie, a pan-oncogenic HPV vaccine.
One possible target is the L2 minor capsid protein. In its
normal context of a virion or VLP, the L2 capsid protein is
immunologically subdominant to the highly immunogenic
L1 capsid protein. However, the amino terminus of L2
produced in Escherichia coli has been shown to induce
broadly cross neutralizing antibodies (Pastrana et al 2005)
and to protect against infection (Chandrachud et al 1995).
Therefore using an L2 vaccine might provide a generic HPV-
neutralizing antibody to protect against many high risk HPV
types and warrants further investigation.
All these potentially controversial issues will be
considered by the Advisory Committee on Immunization
Practices (ACIP) prior to implementation of the vaccine in
the US. ACIP is the federal advisory committee that
formulates recommendations for use after a vaccine is
approved by the US Food and Drug Administration (FDA).
Data considered before recommendations are made address
epidemiology of the infection, immunogenicity, efficacy,
and safety of the vaccine. Acceptability data, programmatic
considerations, and cost-effectiveness data are also
reviewed. Elements of recommendations include appropriate
age, whether booster doses are needed, indications, and
contraindications (Markowitz et al 2005).
In Europe the centralized licensing of new vaccines is
under the remit of the European Medicines Evaluation
Agency (EMEA). Application to a reference member state
(RMS) can also be made as part of a decentralized or mutual
recognition procedure (Wood and Levandowski 2003).
Issues surrounding vaccination policy in the UK are then
under the remit of the Department of Health’s joint
committee on vaccination and immunization (JCVI) which
advises the Secretaries of State for Health (DOH 2005).
Therapeutic vaccines
While an effective prophylactic vaccine appears within
reach, the impact of such a vaccine on cervical cancer rates
will probably not be detectable for several decades after
implementation. This is because of the long latency period
from HPV infection through dysplasia to cervical cancer,
and evidence that a prophylactic vaccine will be of little or
no benefit to women already infected and on this pathway
of disease. Hope for women with established HPV infection
would come in the form of a therapeutic vaccination and
this is likely to be dependant on the induction of cell-
mediated immunity.
The development of therapeutic vaccines is much more
challenging than that of prophylactic vaccines for a variety
of reasons. High grade CIN lesions do express the E6 and
E7 oncoproteins, but at a low level. The lesions are
heterogeneous and genetically unstable and immune evasion
strategies by the virus and evolution of the tumor, such as
human leukocyte antigen (HLA) class I down regulation,
can compromise the effectiveness of any cytotoxic T cells
induced by a therapeutic immunization (Garrido et al 1997;
Stern et al 2001).
The aim of therapeutic vaccines would be to eradicate
high grade CIN lesions and even cervical cancers; howeverTherapeutics and Clinical Risk Management 2006:2(3) 264
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it would clearly be unethical to offer women this type of
disease treatment with a vaccine of unproven efficacy when
effective surgical treatments exist. Therapeutic vaccines are
therefore often initially trialed as adjuvants to conventional
surgical treatment or in cases of advanced disease. Vulval
intraepithelial neoplasia (VIN) is a high risk HPV-associated
lesion which frequently recurs regardless of all currently
available treatments. Although there are some differences
in cervical and vulval HPV-associated lesions, VIN offers
an alternative disease system for testing the efficacy of HPV
vaccination.
There are many different types of therapeutic vaccine
candidates including those based on viral gene-derived
peptides and proteins, DNA, RNA, and various viral and
bacterial vectors. They all aim to induce specific cell-
mediated immunity and, in most cases, the targets are the
E6 and E7 proteins. Therapeutic vaccines have generally
proven safe and immunogenic although proof of significant
clinical efficacy is less evident.
Recent clinical trials which have reported on therapeutic
HPV vaccines are listed in Table 2. This is not intended as
an exhaustive list, but highlights some relevant studies using
a variety of vaccine delivery systems.
One way to present an oncogenic protein to the immune
system is to introduce the gene encoding the protein into
the genome of a recombinant virus. This delivery system
exploits the capability of viruses to infect eukaryotic cells.
Vaccines using viral vectors are highly immunogenic. The
most extensively studied viral vector vaccines use
recombinant vaccinia virus. These have been shown to be
safe and to induce both antibody and T cell responses
(Kaufmann et al 2002; Davidson et al 2003; Corona
Gutierrez et al 2004; Hallez et al 2004; Smith et al 2005).
T cells recognize antigens as peptides presented in
conjunction with major histocompatibility (MHC)
molecules. Peptide fragments of the E6 and E7 proteins can
be directly inoculated as vaccines, such peptide vaccines
are safe and relatively easy to produce. However, their major
drawback lies in the fact that only certain HLA types can
present specific peptides necessitating HLA matching. Since
40% of Caucasians carry the HLA-A2 alleles, the peptides
presented by this allele have been the most widely studied
(Ressing et al 2000). The immunogenicity of peptide
vaccines has been improved by the use of adjuvant
(Muderspach et al 2000).
Researchers at the University of Leiden (Leiden, The
Netherlands) have developed a vaccine consisting of long
overlapping peptides encompassing the complete amino acid
sequences of HPV 16 E6 and E7. Prototypes of this vaccine
were able to induce full regression of papillomavirus-
induced premalignant lesions in rabbits (Vambutas et al
2005) as well as the eradication of established tumors in
mice (Zwaveling et al 2002). A recently completed phase I
study in women with cervical carcinoma showed that 4
vaccinations with this vaccine were safe and lead to a strong
systemic type I T cell immune response in almost all patients.
Currently this vaccine is being tested in 3 different phase II
studies in patients with different stages of disease (van der
Burg, personal communication).
Protein vaccines have the advantage over peptide
vaccines in that they contain all potential epitopes of the
oncogenic protein; in this case usually E6 or E7, thus
circumventing the need for HLA matching. They have been
shown to produce antibody and T cell responses in patients
(de Jong et al 2002). Use of protein-based vaccines with
adjuvants or following modification of the target antigens
by fusion to other molecules such as heat shock proteins
have also been investigated in relation to clinical efficacy
(Frazer et al 2004).
Another vaccine approach uses plasmid DNA-encoding
antigen to provoke immune responses and the vector itself
can exhibit immunostimulatory properties deriving from the
CpG DNA content. This allows for more sustained
presentation of the antigen to the immune system. A currently
active trial employs a DNA vaccine fused to HSP70 (NCI
2005) (see Table 3).
An effective T cell mediated immune response requires
antigen presentation by specialized antigen-presenting cells
(APCs). Dendritic cells are one of the most efficient antigen-
presenting cells and vaccines based on dendritic cells which
have been loaded with tumor antigen have been tested in
clinical trials and shown to produce specific T cell responses
in a proportion of recipients (Ferrara et al 2003).
To increase the clinical efficacy of vaccines currently
under development, a combined approach involving two or
more vaccination technologies has been employed. One such
strategy involves priming of the immune system with a viral
vector vaccine and subsequently boosting with a fusion
protein vaccine (Davidson et al 2004; Smyth et al 2004)
Assessing the immunological response to therapeutic
vaccines can be problematic. This is because the immune
system of an individual with established HPV infection has
already had exposure to viral antigens and in many cases
the tumor induces mechanisms of tolerance that render
antigen-specific immunity ineffective. Pre-existing
immunity means that the definition of a novel immunologicalTherapeutics and Clinical Risk Management 2006:2(3) 265
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c
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p
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a
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response may have to be defined as an arbitrary increase in
an immune marker. In addition a proportion of clinical
lesions show spontaneous regression and therefore any
putative vaccine efficacy must be above and beyond that
predicted to occur spontaneously (Stern et al 2001; Stern
2005).
Prophylactic and therapeutic
An ideal vaccine would have both prophylactic and
therapeutic effects. Such a vaccine would have immediate
benefit in contrast to the inevitable delay before the clinical
impact of prophylactic vaccines. Several candidates are in
development.
Chimeric VLPs build on the technology used to create
VLP vaccines that induce neutralizing antibody. Introducing
E7 fused to the L1 capsid protein into these VLPs induces
CD8 mediated responses in addition to neutralizing antibody
and thus generates a vaccine with potential therapeutic and
prophylactic capability. A phase I clinical trial was
performed in Germany by Medigene (Martinsried,
Germany) and demonstrated both safety and
immunogenicity.
Recent animal studies indicate that as for L1 VLP
vaccines, protection against experimental papillomavirus
challenge by L2 vaccination can be mediated by neutralizing
antibodies (Embers et al 2002). However unlike L1 VLP
vaccination, vaccination with HPVL2 induces antibodies
that cross neutralize diverse mucosal HPV genotypes in vitro
(Pastrana et al 2005). This important distinction from L1
VLP vaccines suggests the possibility of a simple pan-HPV
prophylactic vaccine derived from L2 sequences. Neither
L1 nor L2 vaccines are expected to induce effective
clearance of established HPV lesions probably because of
the lack of capsid protein expression by cervical carcinomas
and infected basal keratinocytes. This is in contrast with
the consistent expression of E6 and E7 proteins through the
spectrum of HPV lesions. TA-CIN is a fusion protein of
HPV 16L2E6E7 it combines the pan HPV neutralizing
potential of L2 with E6 and E7 oncogene directed
therapeutic T cell activity. It has been shown to be safe and
induce both antibody and T cell responses against E6 and
E7 (de Jong et al 2002). The serum of healthy volunteers
vaccinated with TA-CIN has been shown to neutralize not
only HPV16 but also HPV 18 (Gambhira et al 2005). TA-
CIN with an appropriate adjuvant might therefore be a
candidate vaccine with combined prophylactic and
therapeutic potential worthy of further study.
Prospects
A vaccine for preventing persistent HPV infection, the first
necessary step for cervical carcinogenesis, is tangible. Two
major pharmaceutical companies are conducting global
phase III studies and are within sight of regulatory approval
for their prophylactic vaccines. Whilst development of first
generation prophylactic vaccines nears completion there is
scope for an improved second generation of vaccines which
addresses some of the shortcomings of the first generation.
These include expense in manufacturing and distribution
which may reduce impact in the countries where such a
vaccine is most needed, and type specificity such that
screening programs must remain in place.
For the vaccines in late stages of development there are
many issues surrounding implementation yet to be resolved
including who and when to vaccinate, duration of protection,
and synchronization with current screening and other
pathogen vaccination programs.
Many candidate vaccines with therapeutic potential that
use a variety of delivery systems have been trialed and are
the subject of ongoing trials; there are low expectations that
any of the current therapeutic vaccines will have a substantial
public health impact in the near future. An ideal vaccine
would be pan-oncogenic and have both therapeutic and
prophylactic potential. Whilst there are such candidates in
development, the reality is some way off.
Disclosure
Richard Roden is a paid consultant of Knobbe, Martens,
Olsen and Bear, LLC, California, USA.
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